borderline significantP = 0.053
In contrast, N down-staging after neoadjuvant treatment resulted in borderline significant improvement in long-term survival ( P = 0.053) (Figure 5 ).
In contrast, N down-staging after neoadjuvant treatment resulted in borderline significant improvement in long-term survival ( P = 0.053) (Figure 5 ).
We found that T down-staging did not affect long-term outcome, whereas N down-staging appeared to improve survival (borderline significance; P = 0.053).
Subgroup analysis on patients with either unchanged or up-staged disease showed a trend towards worse survival for patients with up-staged T stage ( P = 0.628; Supplementary Figure 1 ).